Showing 2391-2400 of 5956 results for "".
- Lighthouse Guild to Host Lectures on Ophthalmic Drug Approvals, Technological Innovations, and Advocacy for People with Vision Impairmenthttps://modernod.com/news/lighthouse-guild-to-host-lectures-on-ophthalmic-drug-approvals-technological-innovations-and-advocacy-for-people-with-vision-impairment/2481898/Lighthouse Guild will host three lectures on the latest advances in treatment, technology, and advocacy for people who are blind or have vision loss on Thursday, October 19, 2023, 12-1:30 pm ET, at their headquarters, 250 West 64th Street in Manhattan. Lectures:
- SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Diseasehttps://modernod.com/news/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/2481894/SpliceBio has announced the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. Under the terms of
- Staar Surgical Celebrates 30th Anniversary of Implantable Collamer Lens (ICL)https://modernod.com/news/staar-surgical-celebrates-30th-anniversary-of-implantable-collamer-lens-icl/2481892/Staar Surgical is celebrating the 30th anniversary of its proprietary Implantable Collamer Lens (ICL). The first ICLs were implanted by a group of surgeons in October 1993, including Roberto Zaldivar, MD, Founder of the Zaldivar Institute. The early ICLs have evolved into the curre
- RSC Survey Shows Travelers Relying on Glasses and Contact Lenses Have Vacation FOMOhttps://modernod.com/news/rsc-survey-shows-travelers-relying-on-glasses-and-contact-lenses-have-vacation-fomo/2481887/A new poll commissioned by the Refractive Surgery Council (RSC) reveals 50% of Americans with vision prescriptions missed out on at least one activity from their vacation because they wear glasses or contacts. As a result of their ‘vacation FOMO,’ 55% believe having vision c
- Aviceda Announces its Glycomimetic Nanoparticle Candidate AVD-104 Demonstrates Clinical Safety in the Treatment of GAhttps://modernod.com/news/aviceda-announces-its-glycomimetic-nanoparticle-candidate-avd-104-demonstrates-clinical-safety-in-the-treatment-of-ga/2481886/Aviceda Therapeutics announced the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the Euretina congress held in Amsterdam. The phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-
- Johnson & Johnson Vision Presents Data at #Academy23 on ACUVUE MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-presents-data-at-academy23-on-acuvue-max-1-day-contact-lenses/2481885/Johnson & Johnson Vision will present data on the ACUVUE OASYS MAX 1-Day brand family of lenses and research on myopia progression, along with learning opportunities and support of Sight for Kids at the Academy 2023 New Orleans meeting, October 11–14. In celebration
- Alcon Showcases New TOTAL30 Multifocal Lenses and Other Innovations at #Academy23https://modernod.com/news/alcon-demonstrates-commitment-to-innovation-at-academy23-showcasing-total30-multifocal/2481884/Alcon will introduce TOTAL30 Multifocal, the first and only reusable Water Gradient multifocal contact lens, along with the latest advancements in eye care technology at the American Academy of Optometry Annual Meeting (#Academy23) in New Orleans, October 11-14, 2023. Alcon&rs
- Sight Sciences Announces New MIGS Data Demonstrating TCOR Using OMNI Surgical System Lowers IOP and Medication Use at 2 Yearshttps://modernod.com/news/sight-sciences-announces-new-migs-data-demonstrating-tcor-using-omni-surgical-system-lowers-iop-and-iop-reducing-medications-at-2-years/2481863/Sight Sciences announced the results of the large scale, comparative real-world clinical outcomes study of patients treated by three leading minimally invasive glaucoma surgery (MIGS) technologies, which were recently presented at the 41st Congress of the European Society of Cataract an
- Zeiss and Boehringer Ingelheim Partner to Develop Early Detection of Eye Diseases and Prevent Vision Losshttps://modernod.com/news/zeiss-and-boehringer-ingelheim-partner-to-develop-early-detection-of-eye-diseases-and-prevent-vision-loss/2481859/Zeiss Medical Technology and Boehringer Ingelheim announced a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with eye diseases. The partnership aims to bring togeth
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT